Clinical Trials Logo

Peritoneal Mesothelioma clinical trials

View clinical trials related to Peritoneal Mesothelioma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03867578 Active, not recruiting - Mesothelioma Clinical Trials

Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma

Start date: October 10, 2018
Phase: N/A
Study type: Interventional

For cancers, such as mesothelioma, that spread to the lining of the stomach, detecting the cancer is very difficult with CT or MRI scans. Researchers at the University of Chicago want to find out if the new experimental MRI and ultrasound imaging techniques do a better job of detecting these cancers. Researchers will use new MRI and ultrasound techniques to see if it can find evidence of cancer that has spread to the lining of the abdomen, and right now these new techniques are only used for research.

NCT ID: NCT02834169 Active, not recruiting - Clinical trials for Pseudomyxoma Peritonei

French National Registry of Rare Peritoneal Surface Malignancies

RENAPE
Start date: October 2010
Phase: N/A
Study type: Observational [Patient Registry]

Despite advances in the management of and changes in clinical practice, little is known about the epidemiology, patterns of care and outcomes of rare peritoneal surface malignancies patients in France. In order to better understand the characteristics of rare peritoneal surface malignancies and to evaluate treatment strategies, the RENAPE registry aims at the collection of data from patients presenting with a rare peritoneal surface malignancy in France. Data will be entered prospectively in a specifically designed and secured web database. All RENAPE's centres and physicians are invited to register patients with a rare peritoneal surface malignancy diagnosis and to participate to the registry. Data will be evaluated within regular time frames, focusing on types of rare peritoneal surface malignancies, treatment modalities and patient outcomes (e.g. survival, recurrence), thereby contributing to the better understanding of these rare cancers.